Drugs / Vi-Typhoid Conjugate Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03614533 | Dec 2018 → Aug 2019 | typhoid fever | University of Maryland, Baltimore | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vi-Typhoid Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03614533 ↗ |
| Known as | Vi-TCV | “The WHO Strategic Advisory Group of Experts recommends studies to evaluate co-administering Vi-typhoid conjugate vaccine (Vi-TCV) with routine childhood vaccines in...” PMID 30845330 ↗ Mar 2019 |
| Modality | Vaccine | “a single-dose typhoid conjugate vaccine” PMID 30845330 ↗ Mar 2019 |
| Route | Intramuscular | “administered by the intramuscular route” NCT03614533 ↗ |